| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1047234585 |
| P356 | DOI | 10.1186/1471-2369-15-46 |
| P932 | PMC publication ID | 3995549 |
| P698 | PubMed publication ID | 24636040 |
| P5875 | ResearchGate publication ID | 260874057 |
| P2093 | author name string | Jay Wook Lee | |
| Kwon Wook Joo | |||
| Chun-Soo Lim | |||
| Dong Ki Kim | |||
| Jung Pyo Lee | |||
| Yon Su Kim | |||
| Kook-Hwan Oh | |||
| Myounghee Kim | |||
| Kyung-Sang Yu | |||
| Sejoong Kim | |||
| Kwang-Hee Shin | |||
| P2860 | cites work | Challenges in developing evidence-based drug dosing guidelines for adults and children receiving renal replacement therapy | Q84755388 |
| Influenza A(H1N1)v pandemic in the dialysis population: first wave results from an international survey. | Q30381830 | ||
| Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. | Q33813321 | ||
| Big physics, small doses: the use of AMS and PET in human microdosing of development drugs | Q35075780 | ||
| Lack of effect of moderate hepatic impairment on the pharmacokinetics of oral oseltamivir and its metabolite oseltamivir carboxylate | Q35827008 | ||
| Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry. | Q35884220 | ||
| Effects of Uremic Toxins on Transport and Metabolism of Different Biopharmaceutics Drug Disposition Classification System Xenobiotics | Q36634986 | ||
| Regulatory aspects of pharmacokinetic profiling in special populations: a European perspective | Q37288795 | ||
| Pharmacokinetics and dosage adjustment in patients with renal dysfunction. | Q37526589 | ||
| Drug metabolism and pharmacokinetics | Q37550548 | ||
| Nonrenal drug clearance in CKD: Searching for the path less traveled | Q37781450 | ||
| Impact of microdosing clinical study -- why necessary and how useful? | Q37800528 | ||
| What are the important drug use errors in dialysis patients? Pharmacokinetic and pharmacodynamic principles | Q37808682 | ||
| Predictors of loss of residual renal function among new dialysis patients. | Q40775290 | ||
| The phase 0 microdosing concept | Q41942832 | ||
| Microdose Study of 14C-Acetaminophen With Accelerator Mass Spectrometry to Examine Pharmacokinetics of Parent Drug and Metabolites in Healthy Subjects | Q42837250 | ||
| Microdose study of a P-glycoprotein substrate, fexofenadine, using a non-radioisotope-labelled drug and LC/MS/MS. | Q43067629 | ||
| Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). | Q44969186 | ||
| Regulatory Perspectives on Designing Pharmacokinetic Studies and Optimizing Labeling Recommendations for Patients With Chronic Kidney Disease | Q45815953 | ||
| Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs | Q48665583 | ||
| Medication-related problems in ambulatory hemodialysis patients: a pooled analysis | Q51925671 | ||
| Confidence interval criteria for assessment of dose proportionality | Q52069368 | ||
| The pharmacokinetics and tolerability of the oral neuraminidase inhibitor oseltamivir (Ro 64-0796/GS4104) in healthy adult and elderly volunteers | Q53803600 | ||
| Comparative pharmacokinetics between a microdose and therapeutic dose for clarithromycin, sumatriptan, propafenone, paracetamol (acetaminophen), and phenobarbital in human volunteers. | Q54599494 | ||
| The pharmacokinetics and tolerability of oseltamivir suspension in patients on haemodialysis and continuous ambulatory peritoneal dialysis | Q58874874 | ||
| American College of Clinical Pharmacology position statement on the use of microdosing in the drug development process | Q80050350 | ||
| Hemodialysis acutely improves hepatic CYP3A4 metabolic activity | Q80087716 | ||
| Unexplored pharmacokinetic opportunities with microdosing in oncology | Q80624741 | ||
| Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications | Q82667897 | ||
| Pharmacokinetic studies in hemodialysis patients | Q84394949 | ||
| Nonlinear Pharmacokinetics of Oral Quinidine and Verapamil in Healthy Subjects: A Clinical Microdosing Study | Q84472792 | ||
| When to conduct a renal impairment study during drug development: US Food and Drug Administration perspective | Q84755383 | ||
| P921 | main subject | oseltamivir | Q211509 |
| pharmacokinetics | Q323936 | ||
| hemodialysis patient | Q126109077 | ||
| P304 | page(s) | 46 | |
| P577 | publication date | 2014-03-17 | |
| P1433 | published in | BMC Nephrology | Q15750891 |
| P1476 | title | Dose selection method for pharmacokinetic study in hemodialysis patients using a subpharmacological dose: oseltamivir as a model drug | |
| P478 | volume | 15 |
Search more.